Montreal, Canada

GCP Research

Type 2 Diabetes Mellitus

Depression

Depressive Disorder

Type 1 Diabetes Mellitus

Major Depressive Disorder

Diabetic Nephropathies

Vortioxetine

INV-202

AbCellera Biologics

Inversago Pharma

Lundbeck

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to evaluate the effects of single and multiple doses of ABCL635 administered by subcutaneous (SC) injection to healthy men and to postmenopausal women with or without any vasomotor symptoms (VMS) or hot flashes, and to postmenopausal women with moderate-to-severe VMS associated with menopause. The safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) parameters of ABCL635 will be assessed in all study participants; the effects on frequency and severity of VMS will be assessed in postmenopausal women who experience moderate-to-severe symptoms.

Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause

GCP Research | Montreal, Canada

Site insights

Work at this site?

Active trials

Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause

Trial sponsors